Magenta Therapeutics, Inc. (MGTA)

NASDAQ: MGTA · IEX Real-Time Price · USD
1.41
+0.01 (0.71%)
Sep 30, 2022 4:00 PM EDT - Market closed
0.71%
Market Cap 83.04M
Revenue (ttm) n/a
Net Income (ttm) -76.94M
Shares Out 58.89M
EPS (ttm) -1.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 43,013
Open 1.37
Previous Close 1.40
Day's Range 1.34 - 1.48
52-Week Range 0.92 - 8.49
Beta 2.08
Analysts Buy
Price Target 5.10 (+261.7%)
Earnings Date Nov 2, 2022

About MGTA

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug a... [Read more...]

Industry Biotechnology
Founded 2015
CEO Jason Gardner
Employees 70
Stock Exchange NASDAQ
Ticker Symbol MGTA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for MGTA stock is "Buy." The 12-month stock price forecast is 5.1, which is an increase of 261.70% from the latest price.

Price Target
$5.1
(261.70% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors

CAMBRIDGE, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem ce...

1 month ago - GlobeNewsWire

Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights

– MGTA-117 Phase 1/2 clinical trial progress continues and remains consistent with earlier observations of target binding, target cell reductions, rapid drug clearance and a favorable tolerability profi...

1 month ago - GlobeNewsWire

Magenta Therapeutics to Participate in Panel Discussion at the 2022 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem ce...

2 months ago - GlobeNewsWire

After Plunging 49.1% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA)

The heavy selling pressure might have exhausted for Magenta Therapeutics, Inc. (MGTA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall S...

4 months ago - Zacks Investment Research

Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Tria...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to ...

4 months ago - Business Wire

Magenta Therapeutics Trims R&D, Cuts Workforce

Magenta Therapeutics Inc (NASDAQ: MGTA) is cutting 14% of staff and axing a planned dosing optimization trial for a stem cell mobilization med, focused on extending its cash runway into Q2 2024. The cos...

5 months ago - Benzinga

Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to ...

5 months ago - Business Wire

Magenta Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to...

6 months ago - Business Wire

Magenta Therapeutics to Participate in Panel Discussion at the 42nd Annual Cowen Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to...

6 months ago - Business Wire

Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to ...

8 months ago - Business Wire

Magenta Therapeutics to Present at the J.P. Morgan Healthcare Conference and the B.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to...

8 months ago - Business Wire

Magenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization and Targeted Conditioning at ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to...

9 months ago - Business Wire

Big Pharma Is Going Holiday Shopping. Who's Next?

After an infusion of cash from COVID-19 treatments, many companies are on the lookout for acquisitions.

Other symbols: CCXIEPZMHCM
10 months ago - The Motley Fool

Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transpla...

10 months ago - Business Wire

Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 A...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to...

10 months ago - Business Wire

Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transpla...

11 months ago - Business Wire

Magenta Therapeutics to Participate in 2021 Cantor Virtual Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplan...

1 year ago - Business Wire

Magenta Therapeutics Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical Trial

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to mor...

1 year ago - Business Wire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA

NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA).  Such investors are advised...

1 year ago - PRNewsWire

Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to mo...

1 year ago - Business Wire

Magenta Therapeutics Announces Update on U.S. FDA Investigational New Drug Application for MGTA-117 in Patients with ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA) today announced that it has received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its I...

1 year ago - Business Wire

After Plunging 21% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA)

Magenta Therapeutics, Inc. (MGTA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ear...

1 year ago - Zacks Investment Research

Magenta Therapeutics Appoints Caren Deardorf as Chief Commercial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to mo...

1 year ago - Business Wire

Magenta Therapeutics Appoints Thomas Beetham as Chief Legal Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more pat...

1 year ago - Business Wire

Magenta Therapeutics Announces Additional Preliminary Positive Results from Ongoing Phase 2 Clinical Trial of MGTA-14...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more pat...

1 year ago - Business Wire